ESR2 and ischemia: Our current results are consistent with this suggestion as the prior administration of the ERα agonist, PPT, provided significant neuroprotection in our model of pMCAO, while the administration of the same dose ranges of the ERβ agonist, DPN, was not able to provide significant neuroprotection against pMCAO-induced ischemia.